Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open- Label, Dose Escalation Study to Assess the Safety, Pharmacokinetics and Pharmacodynamic Signals of DUR-928 in Patients With Alcoholic Hepatitis

Next Previous
X
Search
Trial Profile

An Open- Label, Dose Escalation Study to Assess the Safety, Pharmacokinetics and Pharmacodynamic Signals of DUR-928 in Patients With Alcoholic Hepatitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Larsucosterol (Primary)
  • Indications Alcoholic hepatitis
  • Focus Adverse reactions
  • Sponsors DURECT Corporation

    • Most Recent Events

    • 01 Jan 2024 Results assessing the safety and pharmacokinetics of larsucosterol in subjects with alcohol-associated hepatitis, published in the American Journal of Gastroenterology.
    • 10 Apr 2023 According to DURECT Corporation media release, additional data from this Phase 2a trial evaluating larsucosterol in alcohol-associated hepatitis has been accepted by the peer-reviewed journal American Journal of Gastroenterology.
    • 29 Aug 2020 Results assessing the safety and pharmacokinetics of DUR-928 in moderate and severe AH patients, presented at The International Liver Congress 2020

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top